



# Patients **Involvement** in Clinical Studies

Šarūnas Narbutas  
Board member, ECPC



EUROPEAN  
**CANCER**  
**PATIENT**  
COALITION



# Clinical Studies from Patient Perspective

- Individual patient is **not aware** about EU health policy, nor EC initiatives: (1) Patient-Partner; (2) Value+; (3) Predict; (4) Respect
- Websites of clinical trials are **not patient - friendly**
- Enrolment procedures are **complex** and often not explained
- Proposal for revised CT directive **lacks vision** and does not assess needs of patient as a priority


# Regulatory Perspective: USA

- Dr. Richard Pazdur, **director of the cancer drug office** at the Food and Drug Administration, said in a recent interview that the new wave of drugs in development — especially for intractable cancers like melanoma — might require individual evaluation.
- “This is an unprecedented situation that will, hopefully, be increasingly common, and it may require a **regulatory flexibility** and **an open public discussion**,” he said.





# Regulatory Perspective: EU



# Types of Patient Involvement



Source: Patient-Partner FP7 Project (2010)



# Involving Patients in Decision Making Contributes to:

- Managing stakeholder **expectations**
  - hope vs hype
- Enhanced **accuracy** of measuring outcomes that will be used for economic evaluation
  - quality of life
  - return to normal life
  - impact on carers
  - well-being rather than health
- Increased accuracy of economic modelling done by industry
  - assuring that direct and **indirect costs** are included
  - involving patients at the stage the issue is converted into economic model
- Enhanced quality of patient involvement during EMA / HTA review
  - **patient reported outcomes**
  - additional value for patients
  - revealing additional evidence



# Patients Vision for Revised CT Directive

- Randomized trials to be **accessible** to all patients concerned, without introducing multi-layer limitations
- Temporary registration to become **available** in late stage clinical trials for rare cancer treatments
- Complementary or alternative methods to be **monitored** besides the existing clinical trials
- Registries to be **linked** with tissue banks
- Facilitated **access** to off-label and early use of drugs



# On the Bright Side

- Rituximab trial for Chronic Fatigue Syndrome succeeded with **3 patients** in a study
- **patientslikeme™** will be adopted for Europe
- Patients number in Ethical Review Committees is **doubling** on a yearly basis


Help **us**  
to  
Help **you**  
to  
Help **ourselves**







Thank You



EUROPEAN  
**C A N C E R**  
**P A T I E N T**  
COALITION

**Šarūnas Narbutas**

[sarunas@ecpc-online.org](mailto:sarunas@ecpc-online.org)

[www.ecpc-online.org](http://www.ecpc-online.org)

**Nothing about us – without us!**